• Publications
  • Influence
The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular
An anti-human interleukin 5 receptor (hIL-5R) humanized immunoglobulin G1 (IgG1) and an anti-CD20 chimeric IgG1 produced by rat hybridoma YB2/0 cell lines showed more than 50-fold higherExpand
  • 1,090
  • 43
Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1.
Removal of the fucose residue from the oligosaccharides attached to Asn297 of human immunoglobulin G1 (IgG1) results in a significant enhancement of antibody-dependent cellular cytotoxicity (ADCC)Expand
  • 224
  • 17
Establishment of FUT8 knockout Chinese hamster ovary cells: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody‐dependent cellular cytotoxicity
To generate industrially applicable new host cell lines for antibody production with optimizing antibody‐dependent cellular cytotoxicity (ADCC) we disrupted both FUT8 alleles in a Chinese hamsterExpand
  • 428
  • 15
IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides.
Fucose depletion from oligosaccharides of human IgG1-type antibodies results in a great enhancement of antibody-dependent cellular cytotoxicity (ADCC). The aim of this study was to clarify the effectExpand
  • 189
  • 11
Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
The structure of asparagine-linked oligosaccharides attached to the antibody constant region (Fc) of human immunoglobulin G1 (IgG1) has been shown to affect the pharmacokinetics and antibody effectorExpand
  • 273
  • 10
Nonfucosylated Therapeutic IgG1 Antibody Can Evade the Inhibitory Effect of Serum Immunoglobulin G on Antibody-Dependent Cellular Cytotoxicity through its High Binding to FcγRIIIa
Purpose: Recent studies have revealed that fucosylated therapeutic IgG1s need high concentrations to compensate for FcγRIIIa-competitive inhibition of antibody-dependent cellular cytotoxicity (ADCC)Expand
  • 172
  • 9
Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies
Most of the existing therapeutic antibodies that have been licensed and developed as medical agents are of the human IgG1 isotype, the molecular weight of which is ∼ 150 kDa. Human IgG1 is aExpand
  • 146
  • 8
Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities.
Enhancement of multiple effector functions of an antibody may be a promising approach for antibody therapy. We have previously reported that fucose removal from Fc-linked oligosaccharides greatlyExpand
  • 162
  • 8
Engineered therapeutic antibodies with improved effector functions
In the past decade, more than 20 therapeutic antibodies have been approved for clinical use and many others are now at the clinical and preclinical stage of development. Fragment crystallizableExpand
  • 142
  • 7
Comparison of cell lines for stable production of fucose‐negative antibodies with enhanced ADCC
Several methods have been described to enhance antibody‐dependent cellular cytotoxicity (ADCC) using different host cells that produce antibody with reduced levels of fucose on their carbohydrates.Expand
  • 107
  • 6